Mechanisms of Induction and Suppression of Viral and Tum

病毒和肿瘤的诱导和抑制机制

基本信息

  • 批准号:
    6558895
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

We have been studying the transformation mechanisms of oncogenes that act through the Mitogen Activated Protein Kinase (MAPK) signaling pathway. Drm (Down-regulated by mos)/Gremlin is a Bone Morphogenetic Protein (BMP) antagonist, initially identified by our lab, which is expressed in a tissue-specific fashion in vivo. With the exception of primary fibroblasts and a few cell lines, most transformed cells in culture fail to express DRM/Gremlin, and we observed that its expression could be suppressed by oncogene transformation, via the MAPK pathway. We hypothesized this loss of expression may be important for the initiation or progression of specific tumors. Our recent work has focused on analyzing Drm's function and mechanism of action in transformed cells. When retroviral and plasmid clones expressing DRM/Gremlin were introduced into transformed cells that expressed little or no Drm/Gremlin, some showed alterations in growth and transformation-associated phenotypic characteristics. To more carefully examine the effect of Drm/Gremlin expression on tumor cell lines, we constructed an ecdysone-inducible Drm/Gremlin construct and generated cell lines that overexpressed Drm/Gremlin following treatment with the inducer Ponasterone A. In parallel we generated cell lines which constitutively overexpress the protein. The p53-negative, primitive neuroectodermal-derived Daoy and the osteosarcoma-derived Saos2 cell lines exhibited slower growth in culture and reduced tumor-forming ability in vivo when Drm/Gremlin was overexpressed. In contrast several p53-expressing cell lines show either increased growth and tumor forming ability, or no change from control cells. In Daoy and Saos2, overexpression of Drm/Gremlin correlated with overexpression of p21Cip1/Waf1, a known inhibitor of the cyclin-dependent kinases involved in progression through the G1/S cell cycle transition. Levels of other growth associated proteins, including ERK1/ERK2, were not affected. Preliminary evidence suggests that p21 promoter activity is decreased following Drm/Gremlin induction in these cells. In contrast, HT1080 (fibrosarcoma) cells exhibit a reduction in p21Cip1/Waf1 levels and increased rates of proliferation and tumoriginicity. These data suggest that the BMP antagonist Drm/Gremlin can act in novel ways to affect tumor cell growth and function.
我们一直在研究通过丝裂原活化蛋白激酶(MAPK)信号通路起作用的癌基因的转化机制。Drm(Down-regulated by mos)/Gremlin是一种骨形态发生蛋白(BMP)拮抗剂,最初由我们实验室鉴定,在体内以组织特异性方式表达。除原代成纤维细胞和少数细胞系外,培养中的大多数转化细胞不能表达DRM/Gremlin,我们观察到其表达可以通过MAPK途径被癌基因转化抑制。我们假设这种表达缺失可能对特定肿瘤的发生或进展很重要。我们最近的工作集中在分析Drm在转化细胞中的功能和作用机制。 当将表达DRM/Gremlin的逆转录病毒和质粒克隆引入表达很少或不表达Drm/Gremlin的转化细胞中时,一些细胞显示出生长和转化相关表型特征的改变。为了更仔细地检查Drm/Gremlin表达对肿瘤细胞系的影响,我们构建了蜕皮激素诱导的Drm/Gremlin构建体,并在用诱导剂Ponasterone A处理后产生过表达Drm/Gremlin的细胞系。同时,我们产生了组成型过表达蛋白质的细胞系。当Drm/Gremlin过表达时,p53阴性的原始神经外胚层来源的Daoy和骨肉瘤来源的Saos 2细胞系在培养中表现出较慢的生长,并且体内肿瘤形成能力降低。相反,几种p53表达细胞系显示出增加的生长和肿瘤形成能力,或与对照细胞相比没有变化。在Daoy和Saos 2中,Drm/Gremlin的过表达与p21 Cip 1/Waf 1的过表达相关,p21 Cip 1/Waf 1是参与G1/S细胞周期转换的细胞周期蛋白依赖性激酶的已知抑制剂。其他生长相关蛋白,包括ERK 1/ERK 2的水平没有受到影响。初步证据表明,p21启动子活性降低后,Drm/Gremlin诱导这些细胞。相比之下,HT 1080(纤维肉瘤)细胞表现出p21 Cip 1/Waf 1水平降低,增殖和致瘤率增加。这些数据表明,BMP拮抗剂Drm/Gremlin可以以新的方式影响肿瘤细胞的生长和功能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DONALD BLAIR其他文献

DONALD BLAIR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DONALD BLAIR', 18)}}的其他基金

MECHANISMS OF INDUCTION AND SUPPRESSION OF VIRAL AND TUMOR-DERIVED ONCOGENE-DEPEN
病毒和肿瘤源性癌基因的诱导和抑制机制
  • 批准号:
    6289092
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Induction and Suppression of Viral and Tumor-derived Oncogene-depe
病毒和肿瘤源性癌基因的诱导和抑制机制
  • 批准号:
    6433015
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Induction and Suppression of Viral and Tum
病毒和肿瘤的诱导和抑制机制
  • 批准号:
    6761464
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STUDIES OF THE V-<I>ETS</I> ETS1 AND FLI1 TRANSCRIPTION FACTORS IN HEMATOPOIETIC
造血中V-<I>ETS</I> ETS1和FLI1转录因子的研究
  • 批准号:
    6289123
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
  • 批准号:
    23K06731
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
  • 批准号:
    23K06616
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
  • 批准号:
    10597799
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
  • 批准号:
    EP/Y024591/1
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10672364
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
  • 批准号:
    10385037
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
  • 批准号:
    10383462
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
  • 批准号:
    10483063
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
  • 批准号:
    2752732
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Studentship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10546865
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了